KEGG   DRUG: Lisocabtagene maraleucel
Entry
D11990                      Drug                                   
Name
Lisocabtagene maraleucel (USAN/INN);
Breyanzi (TN)
Product
BREYANZI (Juno Therapeutics)
Remark
ATC code: L01XL08
Product: D11990<US>
Efficacy
Antineoplastic, Anti-CD19 CAR-T cell
  Disease
Diffuse large B-cell lymphoma, not otherwise specified [DS:H02434]
Follicular lymphoma [DS:H01613]
  Type
Cellular therapy product, CAR-T cell therapy
Target
CD19 [HSA:930] [KO:K06465]
  Pathway
hsa04151  PI3K-Akt signaling pathway
hsa04640  Hematopoietic cell lineage
hsa04662  B cell receptor signaling pathway
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01X OTHER ANTINEOPLASTIC AGENTS
    L01XL Antineoplastic cell and gene therapy
     L01XL08 Lisocabtagene maraleucel
      D11990  Lisocabtagene maraleucel (USAN/INN) <US>
Target-based classification of drugs [BR:br08310]
 Cell surface molecules and ligands
  Other cell surface molecules
   CD molecules
    CD19
     D11990  Lisocabtagene maraleucel (USAN/INN) <US>
New drug approvals in the USA [br08319.html]
 Cellular and gene therapy products
  D11990
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D11990
 Cellular and gene therapy products
  D11990
New drug approvals in Japan [br08318.html]
 Cellular and gene therapy products
  D11990
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D11990
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system